Dogwood Therapeutics Share Holder Equity 2020-2024 | DWTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Dogwood Therapeutics share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Dogwood Therapeutics share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$174.7B
Vertex Pharmaceuticals (VRTX)	$125B
Regeneron Pharmaceuticals (REGN)	$112.1B
Bristol Myers Squibb (BMY)	$107B
Gilead Sciences (GILD)	$106.8B
CSL (CSLLY)	$97.4B
GSK (GSK)	$80.7B
Alnylam Pharmaceuticals (ALNY)	$36.9B
Argenex SE (ARGX)	$32.6B
BioNTech SE (BNTX)	$27.9B
Biogen (BIIB)	$27.9B
Illumina (ILMN)	$23.5B
Moderna (MRNA)	$22B
BeiGene (BGNE)	$21.7B
Genmab (GMAB)	$15.3B
BioMarin Pharmaceutical (BMRN)	$13.4B
Exact Sciences (EXAS)	$12.9B
Vaxcyte (PCVX)	$12.9B
Insmed (INSM)	$12.8B
Incyte (INCY)	$12.8B
Sarepta Therapeutics (SRPT)	$11.8B
Bio-Techne Corp (TECH)	$11.7B
QIAGEN (QGEN)	$10B
Bio-Rad Laboratories (BIO.B)	$9.3B
Roivant Sciences (ROIV)	$8.8B
Legend Biotech (LEGN)	$8.2B
Revolution Medicines (RVMD)	$8.2B
Exelixis (EXEL)	$8.1B
Repligen (RGEN)	$8.1B
Intra-Cellular Therapies (ITCI)	$7.9B